Vistagen Therapeutics Bolsa (NASDAQ: VTGN)

Últimas noticias sobre Vistagen Therapeutics (NASDAQ:VTGN) Bolsa

Vistagen Therapeutics

VistaGen Therapeutics

Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

<ul>
<li>Muñoz to lead Hyundai Motor Company's global business</li>
<li>Continues to serve on the Hyundai Motor Company Board of Directors</li>
</ul>
Hyundai Motor Company (HMC) today announced the appointment of José Muñoz as the company's President and CEO, effective Jan. 1, 2025. Muñoz will lead Hyundai Motor Company's global business, succeeding current President and CEO Jaehoon Chang, who has been promoted to the Vice Chair of Hyundai Motor Group – Automotive Division.

News

Management

HYMLF

HYMTF

Reported Earlier, Hyundai Motor Company Names José Muñoz As President And Chief Executive Officer, Effective January 1, 2025

Macro Economic Events

Econ #s

Economics

France Harmonised Index of Consumer Prices (MoM) For October 0.3% Vs. 0.3% Est.; -1.3% Prior

France Consumer Price Index (MoM) For October 0.3% Vs. 0.2% Est.; -1.3% Prior

OneStream, Inc announced today the pricing of the previously announced underwritten public offering of 15,000,000 shares of its Class&nbsp;A common stock, at a public offering price of $31.00 per share, of which 9,006,948 shares will be sold by selling stockholders and 5,993,052 shares will be sold by OneStream as part of a non-dilutive "synthetic secondary" transaction (the "Synthetic Secondary").

Reported Earlier, OneStream Prices Secondary Offering Of 15M Class A Common Stock At $31/Share

Associated expects to use the net proceeds from this offering for general corporate purposes to support continued organic growth and capital generation, which may include investments in Associated Bank, N.A. and potential balance sheet optimization strategies.

Reported Earlier, Associated Banc-Corp Prices $300M Public Offering Of 12M Common Stock Offering At $25/Share

In a unique perspective, a cryptocurrency analyst equated Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to gunpowder, arguing that sooner or later sovereign nations would be compelled to adopt the leading cryptocurrency.
What Happened: Matt Huang, CEO of cryptocurrency-focused investment firm Paradigm, penned a blog post Thursday, highlighting Bitcoin&#8217;s growing prominence. 
Huang argued that like gunpowder became indispensable after its discovery, the same would eventually pan out for emerging technologies like artificial intelligence, drones, and Bitcoin.
&#8220;Sovereigns can no longer afford to dismiss BTC. From a game theoretic perspective, BTC is like gunpowder, not the iPhone. Christopher,&#8221; the analyst remarked.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Bitcoin for the Sovereign <a href="https://t.co/HD1UpcD6J7">pic.twitter.com/HD1UpcD6J7</a>
&mdash; Matt Huang (@matthuang) <a href="https://twitter.com/matthuang/status/1857127295145902586?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Huang highlighted how calls for the establishment of a Bitcoin strategic reserve have intensified since Donald Trump&#8217;s presidential victory, suggesting the opening of the Overton window for Bitcoin acceptance in America.
&#8220;Sovereigns that build BTC reserves early will benefit from significantly better entry prices. The race to build BTC reserves is on.&#8221;
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41912787/buckle-up-for-the-bull-markets-most-fun-phase-says-industry-expert-bitcoin-ethereum-dogecoin-about-to-enter-the-euphoria-stage?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;Buckle Up&#8217; For The Bull Market&#8217;s &#8216;Most Fun Phase,&#8217; Says Industry Expert: Bitcoin, Ethereum, Dogecoin Abo</a>
Why It Matters: The Republican side vigorously promoted the idea of a Bitcoin reserve leading up to the elections, with none other than President-elect Trump <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40001426/trump-aims-to-make-us-crypto-capital-of-the-planet-well-get-it-done">vowing to establish one</a> if voted to power.
A few days later, Senator Cynthia Lummis (R-Wyo.) <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/40087880/cynthia-lummis-unveils-strategic-bitcoin-reserve-legislation-this-is-our-louisiana-purchas">proposed </a>a bill, called the BITCOIN Act, aimed at creating a strategic Bitcoin stockpile to support America's balance sheet.
The senator reiterated her pledge following the Republican Party&#8217;s electoral triumph last week, as Polymarket odds showed a <a href="https://polymarket.com/event/will-trump-create-a-national-bitcoin-reserve-in-his-first-100-days?tid=1731494882651">35%</a> probability of this happening.
Moreover, emboldened by broader support, Pennsylvania introduced the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41986427/pennsylvania-introduces-bitcoin-strategic-reserve-act-to-invest-up-to-700-million-in-btc">Bitcoin Strategic Reserve Act</a>, hoping to build its own state-held Bitcoin reserve.
Price Action: At the time of writing, Bitcoin was trading at $87,824.55, down 2.35% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA.." target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/41998869/analyst-says-bitcoin-lives-rent-free-in-peoples-minds-after-peter-schiffs-cheeky-social-security-trust-remark">Peter Schiff&#8217;s Cheeky Bitcoin Turnaround Post Earns Reaction From Popular Analyst: &#8216;You Buy It And Become Rich Or You Keep Hating And Turn Crazy&#8217;</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

Bitcoin Is Like Gunpowder And That Is Why Sovereign States Can't Refuse Its Adoption, Says Crypto Analyst

Buybacks

SNDL

Reported Earlier, SNDL Extends Share Repurchase Program With C$100M Authorization, Aiming To Repurchase Up To 13.2M Shares

Equus Total Return, Inc. (NYSE:<a href="https://www.benzinga.com/stock/EQS#NYSE">EQS</a>) ("Equus" or the "Company") reports net assets as of September 30, 2024, of $40.2 million. Net asset value per share decreased to $2.96 as of September 30, 2024, from $3.66 as of June 30, 2024. Comparative data is summarized below (in thousands, except per share amounts):&nbsp;&nbsp;
<figure class="table"> 
<table>
<tbody>
<tr>
<td>As of the Quarter Ended</td>
<td>9/30/2024</td>
<td>6/30/2024</td>
<td>3/31/2024</td>
<td>12/31/2023</td>
<td>9/30/2023 &nbsp;</td>
</tr>
<tr>
<td>Net assets</td>
<td>$40,165</td>
<td>$49,792</td>
<td>$45,892</td>
<td>$48,287</td>
<td>$47,128</td>
</tr>
<tr>
<td>Shares outstanding</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,586</td>
<td>13,518</td>
</tr>
<tr>
<td>Net assets per share</td>
<td>$2.96</td>
<td>$3.66</td>
<td>$3.38</td>
<td>$3.55</td>
<td>$3.49</td>
</tr>
</tbody>
</table>
</figure>

Reported Earlier, Equus Total Return Reports Net Assets As Of September 30, 2024, Of $40.2M; Net Asset Value Per Share $2.96

ZLAB

Reported Earlier, Zai Lab Prices 7.8M American Depositary Shares At $25.50/ADS In $200M Public Offering

Maui Land &amp; Pineapple Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLP#NYSE">MLP</a>) reported quarterly losses of $(0.07) per share. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year. The company reported $3.02 million in sales this quarter. This is a 43.98 percent increase over sales of $2.10 million the same period last year.

Earnings

Maui Land & Pineapple Co Q3 EPS $(0.07) Down From $(0.06) YoY, Sales $3.02M Up From $2.10M YoY

GreenPower Motor Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GP#NASDAQ">GP</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $5.347 million which missed the analyst consensus estimate of $7.967 million by 32.88 percent. This is a 36.35 percent decrease over sales of $8.400 million the same period last year.

Earnings Misses

GreenPower Motor Co Q2 2025 GAAP EPS $(0.18) Misses $(0.16) Estimate, Sales $5.347M Miss $7.967M Estimate

Beam Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(0.12) by 175 percent. The company reported quarterly sales of $11.482 million which missed the analyst consensus estimate of $18.863 million by 39.13 percent. This is a 30.35 percent decrease over sales of $16.486 million the same period last year.

Earnings Beats

BEEM

Beam Global Q3 2024 GAAP EPS $0.09 Beats $(0.12) Estimate, Sales $11.482M Miss $18.863M Estimate

Lantmännen will invest more than 100 million euros in a state-of–the-art <a href="https://www.globenewswire.com/Tracker?data=D-7Y-KVbP6QZknfadXEZ-FyiOL801tmcb6MoPLIt1GBtRzzMxYqB5y0WMAfkDOuP8wF9RdBMPWvDS7IIKC_OkWudCUCt9vi-8ARGYU9fdadf5aFadydlfMoC2c0oEek0wq9shl6f0tFxH4iEsBbG2plhHfhgHB7WME97-NbSZIM6dfFRmaj3AkU_gZXrXeRD6wSfFlbL5NZEKQdFWd05Ix8BUt1dMN_MHpAiD0GLnSSve8knOhEkT3alPDLqD0Z4qqemEbKkxRZ3MJ3oKFuKXBYY26VDZ92n-tTgubAPhQo=">factory in Sweden</a>, while partnering with Ingredion to develop a differentiated portfolio of plant-based protein isolates based on yellow peas. Construction of the production plant will be completed in 2027.

INGR

Reported Earlier, Ingredion And Lantmännen Forge Strategic Alliance To Boost European Plant-Based Protein Market, Invest Over €100M In New Pea Protein Facility

U.K. Trade Balance Non-EU For September -5.31B Vs. -4.85B (Revised) Prior

U.K. Trade Balance For September -16.32B Vs. -15.70B Est.; -15.21B (Revised) Prior

U.K. Monthly Gross Domestic Product (GDP) 3M/3M Change For September 0.1% Vs. 0.2% Est.; 0.2% Prior

U.K. Manufacturing Production (MoM) For September -1.0% Vs. 0.0% Est.; 1.3% (Revised) Prior

U.K. Industrial Production (MoM) For September -0.5% Vs. 0.1% Est.; 0.5% Prior

U.K. Gross Domestic Product (QoQ) Preliminary For Q3 0.1% Vs. 0.2% Est.; 0.5% Prior

U.K. Gross Domestic Product (YoY) Preliminary For Q3 1.0% Vs. 0.1% Est.; 0.7% Prior

Here's the major earnings after the close today

VistaGen Therapeutics GAAP EPS of -$0.35 beats by $0.06, revenue of $0.08M misses by $0.22M

Vistagen Therapeutics, Inc. (VTGN) Q1 2025 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
VistaGen Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/vtgn-stock-quote/">VTGN</a>) just reported results for the first quarter of 2025.<ul><li>VistaGen Therapeutics reported earnings per share of -35 cents. This was above the analyst estimate for EPS of -40 cents.</li><li>The company reported revenue of $84,000.</li><li>This was 72% worse than the analyst estimate for revenue of $300,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/vtgn-stock-earnings-vistagen-therapeutics-for-q1-of-2025/">VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

VTGN Stock Earnings: VistaGen Therapeutics Beats EPS, Misses Revenue for Q1 2025

In a report released yesterday, Jason McCarthy from Maxim Group reiterated a Buy rating on VistaGen Therapeutics (VTGN – Research Report), with a p...

Buy Rating Affirmed on VistaGen Therapeutics Amid Strong Financials and Promising Clinical Trials

Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder

Reports Q2 revenue $183,000, consensus $220,000. "We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another signif...

Vistagen reports Q2 EPS (42c), consensus (39c)

VistaGen Therapeutics GAAP EPS of -$0.42 misses by $0.03, revenue of $0.18M beats by $0.15M

Analyst Jason McCarthy of Maxim Group maintained a Buy rating on VistaGen Therapeutics (VTGN – Research Report), retaining the price target of $12....

VistaGen Therapeutics' Promising Clinical Progress and Strong Financial Position Justify Buy Rating

Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript

ACHV

ARMN

ASXC

CTSO

CURI

DPRO

DRRX

FLUT

GROY

HIVE

IMOS

KNTNF

LAAC

LGMK

MRCY

NVVE

NWHUF

OUST

QFIN

QUIK

REED

RKDA

SHWZ

VTGN

WPRT

ZVRA

Press Releases

Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year

Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine

Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024

Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day

Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024

Vistagen to Present at the 2024 Neuroscience Education Institute Congress

Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update

Comments

Vistagen Therapeutics

Noticias

Últimas noticias sobre Vistagen Therapeutics (NASDAQ:VTGN) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL